Key result
SGLT2 inhibitors alleviate heart failure through non-hypoglycemic mechanisms including reducing circulating volume load, regulating energy metabolism, and mitigating inflammation and oxidative stress.
Why the study?
To review the non-hypoglycemic mechanisms by which SGLT2 inhibitors prevent or alleviate heart failure, supporting their use in patients without type 2 diabetes mellitus.
Design
Review
Authors
Loading...
May extend SGLT2 inhibitor benefits to non-T2DM heart failure; leaves open dedicated randomized confirmation.
This review summarizes the non-hypoglycemic mechanisms by which SGLT2 inhibitors alleviate heart failure, supporting their use in non-diabetic patients.
Zhu et al. (2024) conducted a review in Heart failure. SGLT2 inhibitors was evaluated. SGLT2 inhibitors alleviate heart failure through non-hypoglycemic mechanisms including reducing circulating volume load, regulating energy metabolism, and mitigating inflammation and oxidative stress.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: